AKRO
Akero Therapeutics, Inc.
Latest Form 4:Sale$552KbyRolph Timothy (Chief Scientific Officer) · filed Sep 10, 2025
Akero Therapeutics, Inc. (AKRO) has 15 SEC Form 4 filings (33 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Dec 9, 2025.
Insiders have net sold $552K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Andrew Cheng
- Employees:69
- HQ:South San Francisco, CA, US
- IPO:2019-06-20
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$552K
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
Rolph TimothyFirst filing | Chief Scientific Officer | Sale | 12,500 | $552K | Sep 10 | SEC ↗ |